Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.75
(
2.97%
)
Bitcoin
70,173.45
(
-1.50%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 168870

Monday, 10/28/2013 1:39:03 PM

Monday, October 28, 2013 1:39:03 PM

Post# of 257257

So it only took one quarter for Tecfidera sales to exceed Gilenya's U.S. sales of $273M Wow.

Tecfidera has unquestionably had a great US launch. However, the predictions of a 50% Tecfidera market share in the US I’m seeing from some analysts seem overblown; I doubt that any single MS drug will ever attain such a threshold.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now